London Co. of Virginia Decreases Stake in Haemonetics Corporation $HAE

London Co. of Virginia cut its stake in shares of Haemonetics Corporation (NYSE:HAE) by 7.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 266,034 shares of the medical instruments supplier’s stock after selling 20,481 shares during the quarter. London Co. of Virginia owned approximately 0.57% of Haemonetics worth $12,967,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in HAE. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares during the last quarter. Byrne Asset Management LLC purchased a new stake in shares of Haemonetics in the 3rd quarter valued at approximately $42,000. Hantz Financial Services Inc. raised its holdings in shares of Haemonetics by 792.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock valued at $55,000 after purchasing an additional 998 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Haemonetics in the 2nd quarter valued at $64,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $59.70 on Tuesday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The firm has a market capitalization of $2.77 billion, a P/E ratio of 16.45, a P/E/G ratio of 1.25 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company’s fifty day moving average price is $66.22 and its 200 day moving average price is $64.83.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. During the same quarter in the prior year, the firm posted $1.19 earnings per share. Haemonetics’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, sell-side analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HAE shares. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Barrington Research set a $94.00 price target on Haemonetics in a research note on Friday, February 6th. BTIG Research reaffirmed a “buy” rating and set a $88.00 price target on shares of Haemonetics in a report on Friday, February 6th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.